Safety and tolerability of nintedanib for the treatment of idiopathic pulmonary fibrosis in routine UK clinical practice

In IPF, commencement of antifibrotic therapy in patients with preserved lung volume may increase the duration of therapy http://ow.ly/4HeM30lFS67

Detalles Bibliográficos
Autores principales: Fletcher, Sophie V., Jones, Mark G., Renzoni, Elizabeth A., Parfrey, Helen, Hoyles, Rachel K., Spinks, Katherine, Kokosi, Maria, Kwok, Apollinaris, Warburton, Chris, Titmuss, Vanessa, Thillai, Muhunthan, Simler, Nicola, Maher, Toby M., Brereton, Christopher J., Chua, Felix, Wells, Athol U., Richeldi, Luca, Spencer, Lisa G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2018
Materias:
Original Research Letters
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6194204/
https://www.ncbi.nlm.nih.gov/pubmed/30364342
http://dx.doi.org/10.1183/23120541.00049-2018
Descripción
Sumario:In IPF, commencement of antifibrotic therapy in patients with preserved lung volume may increase the duration of therapy http://ow.ly/4HeM30lFS67

Ejemplares similares